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Aglycosylated IgG produced by hybridoma cells cultured in the presence of tunicamycin was compared 
with normal IgG for its ability to bind to staphylococcal protein A. No differences were found in binding 
or elution profiles. It is concluded that aglycosylation does not produce major structural alterations at the 
&2-t&3 interface of the Fc region of IgG. 
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1. INTRODUCTION 
Staphylococcal protein A is a cell wall component 
which occurs in many strains of Staphylococcus 
aureus and is found to interact with most mam- 
malian IgGs [ 1,2] and also IgA and IgM of certain 
species and subclasses ([3] and references therein). 
The interaction is of high affinity [4,5] and is speci- 
fic for the Fc region of the immunolobulin [6]. The 
protein A molecule comprises 5 domains; 4 are 
highly homologous and are Fc binding whereas the 
fifth, C-terminal domain, acts to anchor the pro- 
tein to the cell wall and does not interact with Fc 
[7,8]. Partial tryptic digestion produces univalent 
low-M, fragments which retain the binding ability 
of the parent molecule [9]. One of the fragments 
(fragment B) has been co-crystallized with human 
Fcyl and shown to bind at the CH2-CH3 domain 
interface [IO, 1 I], a position also implicated from 
work on binding of protein A to IgG fragments 
[4]. The binding of protein A to IgG is therefore 
Abbreviations: DNP, 2,cdinitrophenyl; BSA, bovine 
serum albumin; FCS, foetal calf serum; PBS, phosphate 
buffered saline; SDS-PAGE, sodium dodecyl sulphate 
polyacrylamide gel electrophcresis; CPB, citrate-phos- 
phate buffer containing BSA 
IgG secondary function 
the most structurally well characterized of all the 
IgG secondary interactions. 
The role of the conserved cH2 domain oligosac- 
charide of IgG is not clear, although glycosidase 
treatment has been reported to interfere with IgG 
secondary functions [12,13]. The location of the 
carbohydrate between the two CH2 domains has 
led to proposals that it acts to separate these two 
domains [14] and/or to stabilize the native Fc 
structure [ 15,161. Due to its unique specificity pro- 
tein A has been widely used as an immunological 
tool (review [ 1,2]). Its defined binding site on IgG 
also allows it to be used as a structural probe for the 
integrity of this site. This paper compares the inter- 
action with protein A of normal IgG and aglyco- 
sylated IgG (produced by hybridoma cells cultured 
in the presence of tunicamycin - an antibiotic 
which specifically inhibits N-glycosylation [ 17,181) 
and therefore allows an assessment of whether any 
gross structural changes occur in the Fc region in 
the absence of oligosaccharide attachment. 
2. MATERIALS AND METHODS 
2.1. Materials 
Protein A-Sepharose CL4B was obtained from 
Pharmacia. Tissue culture media were obtained 
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from Gibco, tissue culture vessels from Falcon. 
L-[4,5-3H]Leucine (197 Ci/mmol) and D-[1-*4C]- 
glucosamine hydrochloride (57.9 mCi/mmol) were 
purchased from Amersham International. BSA 
and Dowex 1X8-400 were from Sigma. Protosol 
was from New England Nuclear. Tunicamycin was 
generously provided by Dr M. Potter, NIH, 
Bethesda. 
2.2. Cell culture 
Radio-labelled IgG was produced by culturing 
the hybridoma cell line K3 (a DNP-binding mouse 
IgG2a hybridoma, generously made available by 
Dr B.A. Askonas, Mill Hill) in RPM1 1640/10% 
FCW2 mM gIutamine/5% CO2 & tunicamycin in 
the presence of 2&i/ml [3H]leucine (to label pro- 
tein) and 1 &i/ml [i4C]glucosamine (to label amino 
sugars) essentially as in [18]. Cells (2 x 106/ml) 
were pre-incubated for 4 h + tunicamycin before 
the addition of radiolabel, and the supernatant 
harvested 36 h later. Preliminary experiments had 
indicated that under these conditions a tunicamycin 
concentration of 2/cg/ml (for the particular batch 
of tunicamycin used) produced total inhibition of 
glycosylation and so this was the concentration 
used. 
2.3. Isolation of radiolabelled IgG 
Radiolabelled IgG was isolated on columns of 
DNP-lysine-Sepharose. After washing with PBS 
the IgG was eluted with 50mM DNP-glycine 
pH 7.2, which was subsequently removed on a 
Dowex 1X8-400 column equilibrated in PBS. 
2.4. SDS-PAGE 
Radiolabelled IgG samples were run on 9% 
SDS-PAGE [19]. Reduction of samples was with 
2-mercaptoethanol. Gels were sliced into 2-mm 
sections and the radioactivity solubilized into 
0.3 ml of Protosol: water (9: 1) overnight before 
counting in tolulene-based scintillant. 
2.5. Protein A-Sepharose chromatography 
For the protein A-Sepharose chromatography 
the buffer system used was 0.05 M citric acid/O. 1 M 
NazHPOJBSA (1 mg/ml) (CPB). The BSA (which 
does not interact with protein A) was found to be 
necessary to prevent non-specific adsorption of the 
IgG at such low concentrations to the glassware. 
The column of protein A-Sepharose (16mm x 
228 
4.4 mm) was equilibrated with CPB (pH 8) and the 
labelled IgG loaded in the same buffer. After 
washing with this buffer, the column was eluted 
with a linear gradient of CPB (pH 8) to CPB 
(pH 3) (25 ml + 25 ml) at a flow rate of 30 ml/h. 
The fractions (0.5 ml) were counted in a tolulene- 
based scintillant . 
3. RESULTS 
The SDS-PAGE profiles of K3 IgG radio- 
labelled in culture in the presence and absence of 
2pg/ml tunicamycin are shown in fig.1. As has 
been demonstrated [18,20,21], the IgG produced is 
still secreted from the cells and from fig. 1 it is seen 
that under the conditions used it is totally aglyco- 
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Fig. 1. SDS-PAGE (9010 acrylamide) of IgG synthesized 
by the K3 cell line cultured in medium containing 
13H]leucine and [14C]glucosamine. (A) in the absence of 
tunicamycin, (B,C) in the presence of 2pg/ml tuni- 
camycin. In (A) and (B) the samples were reduced with 
2-mercaptoethanol; (C) is unreduced. 
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Glycosylated 
Fig.2. The binding and pH elution profiles of radiolabel- 
led glycosyl and aglycosyl IgG to protein A-Sepharose. 
sylated. In the absence of reducing agents the agly- 
cosylated IgG migrates as a single 150 000 M, band 
indicating that assembly to a disulphide-linked 
H2L2 unit occurs normally in the absence of car- 
bohydrate. Since the aglycosylated IgG still binds 
to the DNP-Sepharose affinity column hapten 
binding is also not affected. The binding/elution 
profiles of these biosynthetically radiolabelled 
glycosylated and aglycosylated forms of K3 IgG to 
protein A-Sepharose are shown in fig.2. Both 
IgGs are found to bind equally well to the column. 
Moreover, both glycosylated and aglycosylated 
proteins elute with the gradient in an identical 
manner, at the expected position for a mouse 
IgG2a [22]. 
4. DISCUSSION 
Immobilized staphylococcal protein A has been 
widely used in the affinity purification of IgG. 
More recently it has been found that the conditions 
for elution of IgG from protein A-Sepharose dif- 
fer for different IgG subclasses. This has been used 
in the purification of IgG subclasses of many 
species [22-271. Perhaps the best example is with 
mouse IgG [22], where each of the main subclasses 
(1, 2a and 2b) may be separated from each other 
by their position of elution from protein A-Sepha- 
rose using a series of buffers of descending pH. 
Since no other mouse Ig class binds, this affords a 
rapid and effective purification protocol which 
would be extremely difficult by more conventional 
techniques. By implication therefore, the position 
of elution from a protein A-Sepharose column by 
a descending pH gradient reflects the differing 
structure/sequence around the protein A binding 
site. This is well illustrated in the case of human 
IgG3 which is not usually considered to bind pro- 
tein A. The lack of binding is explained by the 
substitution of His-435 in the protein A binding 
site by an arginine residue; restoring the histidine 
as is found in a y3 allotypic variant, restores binding 
[28]. The binding to, and conditions of elution 
from protein A-Sepharose therefore offer an indi- 
cation of any structural changes around the pro- 
tein A binding site. Such an approach has been 
used to show that the hinge-deleted human 
IgGl(Dob) binds protein A normally [29], re- 
flecting the normal Fc structure found in X-ray 
crystallographic studies on this protein 1301. 
The results presented here show that aglyco- 
sylated IgG also binds to protein A in a manner 
which is indistinguishable from normal IgG. The 
implications of this are 2-fold. Firstly, protein 
A-Sepharose may be used for purification of 
aglycosylated IgG in the same manner as for the 
parent IgG, if required. More importantly how- 
ever, these results indicate that the conformation 
of the Cu2-Cu3 domain interface as sensed by 
protein A remains the same upon aglycosylation. 
The protein A binding site is formed by the uni- 
que longtitudinal interaction of the Cu2 and CH3 
domains of IgG [lo,1 11. Any disruption of this 
quaternary interaction would be expected to result 
in a loss of binding (individual CH2 and CH3 
domains do not retain any affinity for protein A 
[4]). Therefore it is implied that the characteristic 
(i.e., ‘split’ Cu2) orientation of the Cr.12 and Cn3 
domains found in the glycosylated Fc is retained in 
aglycosylated IgG, since any perturbation to their 
quaternary interaction would be expected to affect 
the protein A binding region. It should be noted 
however, that although gross structural effects 
upon aglycosylation seem likely in the light of 
these results, minor structural alterations or de- 
stabilization [ 15,161 localized to the immediate 
area of the carbohydrate may not be reflected in 
altered protein A binding. 
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